Thiazolidinedione treatment inhibits bile duct proliferation and fibrosis in a rat model of chronic cholestasis

Figure 1 Effects of oral supplementation with TGZ on liver pathology in control rats (A and B) and bile duct-ligated rats (C-J). Animals received sham operation (A and B) or were subjected to BDL for 2 wk (C-F) or for 4 wk (G-J).

Figure 2 Effects of TGZ on type I procollagen expression in bile duct-ligated rats.

Figure 3 TGZ inhibits collagen accumulation in bile duct-ligated rats in different experimental groups. ^aP<0.05 vs Sham, ^cP<0.05 vs BDL.

Figure 4 TGZ reduces accumulation of SMA-positive cells after BDL in different experimental groups. A: Sham; B: TGZ; C: BDL; D: BDL/TGZ.

Figure 5 Effects of TGZ on SMA expression in rats undergoing BDL. ^aP<0.05 vs Sham, ^cP<0.05 vs BDL.

Figure 6 Development of ductular reaction is inhibited in bile duct ligated and TGZ-treated rats in different experimental groups. (A: Sham; B: TGZ; C, E and G: BDL; D, F, and H: BDL/TGZ) for different periods of time (C and D: 1 wk; E and F: 2 wk; A, B, G, and H: 4 wk).

Figure 7 Effects of TGZ on liver GGT activity in bile duct-ligated rats. ^aP<0.05 vs Sham, ^cP<0.05 vs BDL.